Loading...

KZR KEZAR LIFE SCIENCES INC Company Mergers 8-K Filing

KZR

KZR

KEZAR LIFE SCIENCES INC

(KZR)

2025 8-K

Summary

Summary

Debt Repayment Complete

Regulatory Update

Financial Results Announcement

Financial Statements

Management Change

Financial Results

Kezar Presentation

Financial Estimates

Rights Agreement Amendment

Nasdaq Compliance

Financial Results

Stock Split Approved

Rights Plan Adopted

Acquisition Proposal

Development Update

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Estimates

Earnings Reports

Departure of Chief Medical ...

Reduction in Force and CEO ...

Collaboration and License A...

Clinical Trial Update

Earnings Reports

Stock Option Repricing

Amendment to Certificate of...

Earnings Reports

Departure of Directors or C...

Financial Results Announcement

Resignation of Christopher ...

Financial Estimates

External Links:

On October 16, 2025, Kezar Life Sciences announced its regulatory update on the zetomipzomib program for autoimmune hepatitis and revealed a cash position of $90.2 million as of September 30, 2025, along with changes to its Rights Agreement.

AI Assistant

KEZAR LIFE SCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.